Riociguat Clinical Effects Studied in Patients With Insufficient Treatment Response to Phosphodiesterase-5 Inhibitor

NCT02007629 | Completed Phase 3

• 2 other identifiers: 167192013-001759-10
• Study Type: interventional
• Target: 61
• Locations: 9 countries
• Sites: 27

Brief Summary

BAY63-2521 Riociguat leads to the relaxation of smooth muscle cells in pulmonary arteria and may also inhibit abnormal remodeling of lung blood vessels. In patients with pulmonary arterial hypertension Riociguat showed to reduce the pulmonary blood pressure and improved the right heart function without unacceptable side effects. Here dose of Riociguat will be adjusted over 8 weeks then a Maintenance Phase of 16 weeks follows. Patients with Pulmonary Arterial Hypertension treated with stable doses of Phosphodiesterase Type-5 Inhibitors (Eg Sildenafil, Tadalafil) not appropriately responding to therapy will be included. Based on previous evidence and on the different modes of action an improvement of exercise capacity, heart function and quality of life may be expected if PDE5i treatment is transitioned to riociguat. Where Riociguat is pending market approval or reimbursement once the treatment phase is completed drug can be made available for another 18 months (Extended Drug Supply Phase - EDSP) under study conditions. Patients may also transition at the end of the maintenance period or any time during the EDSP to any program that is intended to provide riociguat until drug approval/reimbursement, e.g. a long-term extension study, compassionate use or named patient program. Study termination is also possible at any time.

Conditions

Hypertension, Pulmonary

Outcome Measures

Primary Outcomes (1)

• Change from baseline in 6 Minute Walking Distance (6MWD)

  6MWD test was used to measure the subjects functional exercise capacity. Subjects were instructed to walk alone, not run, from one end to the other end of the walking course, at their own pace, while attempting to cover as much ground as possible in 6 minutes. No "warm-up" period was performed before the test. Investigators have not walked with the subjects. This was an encouraged test (the person conducting the test encouraged subjects to walk farther or faster by using only standardized phrases).

  Baseline, Week 12 and Week 24

Other Outcomes (7)

• Change From Baseline in Cardiac Index

  Baseline, Week 24

• Change From Pre-treatment in N-Terminal Pro-Brain Natriuretic Peptide (NTproBNP)

  Baseline, Week 12 and Week 24

• Change From Baseline in World Health Organization Functional Class (WHO FC)

  Baseline, Week 12 and Week 24

Study Arms (1)

Riociguat

EXPERIMENTAL

Subjects received riociguat film coated immediate-release (IR) tablet 3 times a day (tid) with or without food at a starting dose of 1.0 milligram (mg) and increased by 0.5 mg increments at 2-weekly intervals to a maximum of 2.5 mg tid, until Week 8 (titration phase). An optimal dose was determined based on systolic blood pressure (SBP) and well-being. Thereafter, riociguat continued at the optimal individual dose until Week 24 (Main phase). Dose reductions or stop of study medication for safety reasons were allowed at any time. Increases or re-increases in 0.5 mg steps (maximum dose 2.5 mg) were possible at the investigator's discretion weighing the benefit with potential risks implied. Subjects were offered participation in EDSP and received riociguat 2.5 mg film coated IR tablet 3 tid with or without food for 18 months or until reimbursement.

Drug: Riociguat (Adempas, BAY63-2521)

Interventions

Riociguat (Adempas, BAY63-2521) DRUG

Riociguat / BAY63-2521 film-coated tablets will be used in this study at a dosage of either 0.5, 1.0, 1.5, 2.0, and 2.5 mg. 3 times daily

Riociguat

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female patients (18 -75 years of age) with idiopathic, familial, drug/toxin induced and associated PAH due to congenital heart disease (Group I / Dana Point Classification of PH) demonstrating insufficient response to treatment with PDE-5i for at least 3 months
• Patients with and without endothelin receptor antagonist (ERA) therapy
• World Health Organization Functional Class (WHO FC) III at screening
• minute walking distance (6MWD) of 165-440 m
• Cardiac index \<3.0 L/min/m\*2.

You may not qualify if:

• Evidence of clinically significant restrictive or obstructive parenchymal lung diseases
• Diffusing capacity of the lung for carbon monoxide (DLCO) \<30% predicted
• History or active state of serious hemoptysis / pulmonary hemorrhage including those managed by bronchial artery embolization
• Patients unable to perform a valid 6MWD test
• Pregnant women (i.e. positive pregnancy test or other signs of pregnancy), or breast feeding women, or women with childbearing potential not using a combination of 2 effective methods of birth control, for example a combination of condoms with a safe and highly effective contraception method (prescription oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device) or a double barrier method is used throughout the study.

Sponsors & Collaborators

• Bayer: lead

Study Sites (27)

Unknown Facility

La Jolla, California, 92093, United States

Location

Unknown Facility

Sacramento, California, 95817, United States

Location

Unknown Facility

Iowa City, Iowa, 52242-1089, United States

Location

Unknown Facility

Boston, Massachusetts, 02111, United States

Location

Unknown Facility

St Louis, Missouri, 63110, United States

Location

Unknown Facility

Pittsburgh, Pennsylvania, 15212, United States

Location

Unknown Facility

Providence, Rhode Island, 02903, United States

Location

Unknown Facility

Bruxelles - Brussel, 1070, Belgium

Location

Unknown Facility

Leuven, 3000, Belgium

Location

Unknown Facility

Montreal, Quebec, H3T 1E2, Canada

Location

Unknown Facility

Prague, 12808, Czechia

Location

Unknown Facility

Grenoble, 38043, France

Location

Unknown Facility

Le Kremlin-Bicêtre, 94275, France

Location

Unknown Facility

Marseille, 13005, France

Location

Unknown Facility

Heidelberg, Baden-Wurttemberg, 69126, Germany

Location

Unknown Facility

Regensburg, Bavaria, 93053, Germany

Location

Unknown Facility

Hanover, Lower Saxony, 30625, Germany

Location

Unknown Facility

Cologne, North Rhine-Westphalia, 50924, Germany

Location

Unknown Facility

Dresden, Saxony, 01307, Germany

Location

Unknown Facility

Leipzig, Saxony, 04103, Germany

Location

Unknown Facility

Rome, Lazio, 00161, Italy

Location

Unknown Facility

Pavia, Lombardy, 27100, Italy

Location

Unknown Facility

Zurich, 8091, Switzerland

Location

Unknown Facility

Newcastle upon Tyne, Tyne and Wear, NE7 7DN, United Kingdom

Location

Unknown Facility

Clydebank, West Dunbartonshire, G81 4DY, United Kingdom

Location

Unknown Facility

London, NW3 2QG, United Kingdom

Location

Unknown Facility

London, SW3 6NP, United Kingdom

Location

Related Publications (2)

• Hoeper MM, Klinger JR, Benza RL, Simonneau G, Langleben D, Naeije R, Corris PA. Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors. Respir Med. 2017 Jan;122 Suppl 1:S18-S22. doi: 10.1016/j.rmed.2016.11.001. Epub 2016 Nov 5.

  PMID: 27887774 RESULT

• Hoeper MM, Simonneau G, Corris PA, Ghofrani HA, Klinger JR, Langleben D, Naeije R, Jansa P, Rosenkranz S, Scelsi L, Grunig E, Vizza CD, Chang M, Colorado P, Meier C, Busse D, Benza RL. RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors. Eur Respir J. 2017 Sep 9;50(3):1602425. doi: 10.1183/13993003.02425-2016. Print 2017 Sep.

  PMID: 28889107 RESULT

Related Links

• Click here to find information about studies related to Bayer Healthcare products conducted in Europe.

MeSH Terms

Conditions

Hypertension, Pulmonary

Interventions

riociguat

Condition Hierarchy (Ancestors)

Lung Diseases; Respiratory Tract Diseases; Hypertension; Vascular Diseases; Cardiovascular Diseases

Study Officials

• Bayer Study Director

  Bayer

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 6, 2013
• First Posted: December 11, 2013
• Study Start: February 18, 2014
• Primary Completion: December 29, 2016
• Study Completion: December 29, 2016
• Last Updated: February 21, 2019

Record last verified: 2018-12

Locations

GB (4); CA (1); BE (2); CZ (1); DE (6); US (7); IT (2); CH (1); FR (3)